Back to top
more

The Medicines Company (MDCO)

(Delayed Data from NSDQ)

$31.89 USD

31.89
912,624

+0.61 (1.95%)

Updated May 3, 2019 04:00 PM ET

After-Market: $31.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for FNY

Ekta Bagri headshot

3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

by Ekta Bagri

With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Alnylam's Kidney Disease Drug Succeeds in Late Stage Study

by Zacks Equity Research

Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.

Ekta Bagri headshot

5 Biotech Stocks That Have More Than Doubled This Year

by Ekta Bagri

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

by Neena Mishra

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Alnylam Gets Second Product Approval Amid Stiff Competition

by Zacks Equity Research

Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Kinjel Shah headshot

4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

by Kinjel Shah

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

A Day of Mergers: TIF, AMTD, MDCO & More

by Zacks Equity Research

A Day of Mergers: TIF, AMTD, MDCO & More

Mark Vickery headshot

Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More

by Mark Vickery

While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.

Novartis (NVS) to Acquire The Medicines Company for $9.7B

by Zacks Equity Research

Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.

The Medicines Company to be Acquired by Novartis for $9.7B

by Zacks Equity Research

The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.

Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria

by Zacks Equity Research

Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.

Implied Volatility Surging for Medicines Company (MDCO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.

Medicines Company Up on Rumors of Potential Buyout by Novartis

by Zacks Equity Research

The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.

Sanghamitra Saha headshot

Healthcare ETF (RYH) Hits New 52-Week High

by Sanghamitra Saha

This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

Medicines Company Posts Full Inclisiran Data From ASCVD Study

by Zacks Equity Research

The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss

by Zacks Equity Research

The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.

Medicines Co. (MDCO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Medicines Co. (MDCO) delivered earnings and revenue surprises of -9.52% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Medicines Company's Inclisiran Succeeds in Pivotal Studies

by Zacks Equity Research

The Medicines Company's (MDCO) PCSK9 inhibitor, inclisiran, meets primary endpoint of LDL-C reduction in the remaining two phase III studies in the ORION program. Shares up.

Medicines Company (MDCO) Jumps: Stock Rises 5.5%

by Zacks Equity Research

Medicines Company (MDCO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.